Chiglitazar vs Lanifibranor
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: PPAR (pan-agonist) · full Type 2 Diabetes pipeline
Chiglitazar · Bilessglu
Marketed by Chipscreen Biosciences
NCT02173457 · Phase 3 · completed
In this randomized, double-blind, active-controlled Phase 3 trial, 740 patients with type 2 diabetes were randomized to chiglitazar (32mg or 48mg) or sitagliptin. At 24 weeks, chiglitazar met its non-inferiority margin against sitagliptin on HbA1c reduction, with very small treatment differences of -0.04 and -0.08 percentage points.
Next expected readout: December 2030 · NCT07303803 (registry estimate)
Reported efficacy
percentage of HbA1c change from baseline (24 weeks): RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008. (met)
Result source: NCT04807348
Lanifibranor
Developed by Inventiva and partners
NCT05232071 · Phase 2 · completed
This trial was randomized, blinded, and placebo-controlled, and its posted results showed lanifibranor and lanifibranor-plus-empagliflozin both significantly lowered HbA1c versus placebo at 24 weeks. However, the trial enrolled only 39 patients across three arms, explicitly designed as an early proof-of-concept study, which is too small to serve as strong, confirmatory evidence on its own.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Assessment of the effect of lanifibranor alone compared to placebo and the effect of lanifibranor in combination with empagliflozin compared to placebo on absolute change in HbA1c from baseline (Week 0) to Week 24 (Date of randomisation until the end of treatment at week 24): HbA1c absolute change from baseline to Week 24: lanifibranor (800mg) -1.14% and lanifibranor+empagliflozin -1.59%, vs +0.26% increase on placebo; the study achieved the primary efficacy endpoint (met)
Result source: NCT05232071
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Chiglitazar | Lanifibranor |
|---|---|---|
| HbA1c, change | -1.1% vs -0.5%a−0.6 vs placeboNCT048073481 other result
| -0.7% vs -0.1%−0.6 vs placeboNCT034590792 other results
|
| Body weight, change (kg) | —Not posted · NCT02173457 | —Not reported |
| HbA1c below 7% | —Not posted · NCT02173457 | —Not reported |
| Fasting plasma glucose, change | —Not posted · NCT02173457 | —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT02173457 | —Not reported |
HbA1c, change
- Chiglitazar
- -1.1% vs -0.5%a−0.6 vs placeboNCT04807348
1 other result
- -0.9% vs -0.5% NCT04807348
- Lanifibranor
- -0.7% vs -0.1%−0.6 vs placeboNCT03459079
2 other results
- -1.1% vs 0.3% NCT05232071
- -1.6% vs 0.3% NCT05232071
Body weight, change (kg)
- Chiglitazar
- —Not posted · NCT02173457
- Lanifibranor
- —Not reported
HbA1c below 7%
- Chiglitazar
- —Not posted · NCT02173457
- Lanifibranor
- —Not reported
Fasting plasma glucose, change
- Chiglitazar
- —Not posted · NCT02173457
- Lanifibranor
- —Not reported
3-point MACE (% with event)
- Chiglitazar
- —Not posted · NCT02173457
- Lanifibranor
- —Not reported
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Chiglitazar: 0 of 4 rows · Lanifibranor: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Chiglitazar | Lanifibranor |
|---|---|---|
| Dropout rate | — | 30%a NCT03459079 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | — | 20%a NCT03459079 · Phase 2 · registry result, not featured evidence |
| Serious AEs | — | 5%a NCT03459079 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | — | a diarrhoea 26.3% (placebo 16.7%) elevated lipase level 25% (placebo 16.7%) anaemia 20% (placebo 11.1%) NCT03459079 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Chiglitazar
show 1 more result
Lanifibranor
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Chiglitazar's landscape · Lanifibranor's landscape